Disease · MONDO_0005111
Epstein-Barr virus infection
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Epstein-Barr virus infection. Diseases, record MONDO_0005111. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005111
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
EBV INFECT, EBV Infections, EBV infection, EPSTEIN BARR VIRUS INFECT, Epstein Barr Virus Infections, Epstein-Barr virus infection (disorder), Epstein-Barr virus infectious disease, HERPESVIRUS 4 INFECT HUMAN, HUMAN HERPES VIRUS 4 INFECT, HUMAN HERPESVIRUS 4 INFECT, Herpesvirus 4 Infections, Human, Human Herpes Virus 4 Infections, Human Herpesvirus 4 Infections, Human gammaherpesvirus 4 caused disease or disorder, Human gammaherpesvirus 4 disease or disorder, Human gammaherpesvirus 4 infectious disease, INFECT EBV, INFECT EPSTEIN BARR VIRUS, Infections, EBV, Infections, Epstein-Barr Virus, Tumor Virus Infections, Virus Infections, Epstein-Barr
- Open Targets
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LENALIDOMIDE | CHEMBL848 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SINTILIMAB | CHEMBL4297829 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MAGNESIUM SULFATE | CHEMBL3989857 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TENOFOVIR | CHEMBL3989702 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TUCIDINOSTAT | CHEMBL3621988 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VALACYCLOVIR | CHEMBL1349 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ACETAMINOPHEN | CHEMBL112 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DIPHENHYDRAMINE | CHEMBL657 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TRAXIVITUG | CHEMBL5314887 | Antibody | Phase 1 | TTD | 1 | 0 | 0 | Drugs and targets |
Targets11
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CRBN | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 2 | https://conductscience.org/library/genes/51185 | Drugs and targets |
| CUL4A | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 2 | https://conductscience.org/library/genes/8451 | Drugs and targets |
| DDB1 | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 2 | https://conductscience.org/library/genes/1642 | Drugs and targets |
| FAAH | Fatty-acid amide hydrolase 1 | 1 | Anandamide amidohydrolase inhibitor | Phase 1 | https://conductscience.org/library/genes/2166 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 1 | Histamine H1 receptor antagonist | Phase 1 | https://conductscience.org/library/genes/3269 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 1 | B-lymphocyte antigen CD20 binding agent | Phase 2 | https://conductscience.org/library/genes/931 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 1 | Programmed cell death protein 1 antagonist | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 1 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 1 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| RBX1 | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 2 | https://conductscience.org/library/genes/9978 | Drugs and targets |
1 to 10 of 11
See all 11 targetsTrials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02496676 | Magnesium Supplementation in People With XMEN Syndrome | Phase 1/2 | 8 | 2022-01-26 | XMEN | MAGNESIUM SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT04518982 | Sintilimab and Lenalidomide as a Treatment for CAEBV | Phase 2 | 51 | CAEBV | LENALIDOMIDE, SINTILIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT07133776 | Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases. | Phase 1/2 | 30 | Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor, Tenofovir, Chidamide, Lenalidomide | LENALIDOMIDE, TENOFOVIR, TUCIDINOSTAT | Its record names the disease | ClinicalTrials.gov | |
| NCT00274404 | Controlled Trial of Valacyclovir in Infectious Mononucleosis | Phase 1/2 | 20 | Infectious Mononucleosis | VALACYCLOVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT07261215 | Zuberitamab for EBV Infection Post-Allo-HSCT | Phase 2 | 20 | HSCT, EBV Infection | RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01070797 | Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) | Phase 1 | 10 | Adenovirus Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections, Stem Cell Transplant | ACETAMINOPHEN, DIPHENHYDRAMINE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Magnesium vs Placebo: Participants With 2-fold or Greater Increase in NKG2D Expression in CD8 T+ Cells After Magnesium Supplementation as Compared to Placebo - Phase 1 | 0 of 3 | 0 of 3 | 6 | NCT02496676 | Trial comparisons |
| Magnesium vs Placebo: Participants With 2-fold or Greater Increase in NKG2D Expression in CD8 T+ Cells After Magnesium Supplementation as Compared to Placebo - Phase 1 | 0 of 1 | 0 of 1 | 2 | NCT02496676 | Trial comparisons |
| Magnesium vs Placebo: Participants With a ≥0.5 Log Reduction in the Number of EBV-infected B Cells After Magnesium Supplementation as Compared to Placebo - Phase 1 | 0 of 1 | 0 of 1 | 2 | NCT02496676 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005111
GET https://conductscience.org/api/diseases/v1/MONDO_0005111/drugs